Senior insider sale
Chief R&D Officer at NEKTAR THERAPEUTICS — senior position signals high conviction
$219.1K
5.20K shares
What this filing means
ZALEVSKY JONATHAN plans to sell 5.20K shares of NEKTAR THERAPEUTICS valued at approximately $219.1K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 2/18/2026ACC: 0001959173-26-001135
Officer· Chief R&D Officer
Since Oct 2019
5.20K
Shares to sell
$219.1K
Approx. market value
180.00
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months1
Restricted Stock Vesting
Compensation
2/13/2026
180.00Total acquired180.00
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/13/2026 | Restricted Stock Vesting Compensation | 180.00 | — |
| Total | 180.00 | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
3.87K
Market value
$137.9K
1/20/2026
—Completed
Units to sell
1.16K
Market value
$68.1K
11/25/2025
Planned — Approximate Date
NASDAQPlanned
Units to sell
180.00
Market value
$13.1K
2/18/2026
Total
Units
5.20K
Value
$219.1K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
1/20/2026 | 3.87K | $137.9K | — | Completed |
11/25/2025 | 1.16K | $68.1K | — | Completed |
| Planned — Approximate Date | ||||
2/18/2026 | 180.00 | $13.1K | NASDAQ | Planned |
| Total | 5.20K | $219.1K | ||